S&P 500   4,590.06 (+0.84%)
DOW   35,676.27 (+0.52%)
QQQ   383.15 (+0.83%)
AAPL   152.45 (+2.42%)
MSFT   322.85 (-0.10%)
FB   314.45 (+0.71%)
GOOGL   2,905.86 (-0.63%)
TSLA   1,069.50 (+3.05%)
AMZN   3,431.77 (+1.16%)
NVDA   246.62 (+0.86%)
BABA   169.75 (+0.31%)
NIO   39.82 (+1.30%)
CGC   13.06 (+2.19%)
GE   104.55 (+0.67%)
AMD   121.63 (-0.53%)
MU   69.69 (+2.12%)
T   25.50 (+1.76%)
F   17.00 (+9.61%)
ACB   6.98 (+2.05%)
DIS   170.20 (+0.38%)
PFE   43.29 (+0.74%)
BA   206.40 (-0.10%)
AMC   35.24 (+1.38%)
S&P 500   4,590.06 (+0.84%)
DOW   35,676.27 (+0.52%)
QQQ   383.15 (+0.83%)
AAPL   152.45 (+2.42%)
MSFT   322.85 (-0.10%)
FB   314.45 (+0.71%)
GOOGL   2,905.86 (-0.63%)
TSLA   1,069.50 (+3.05%)
AMZN   3,431.77 (+1.16%)
NVDA   246.62 (+0.86%)
BABA   169.75 (+0.31%)
NIO   39.82 (+1.30%)
CGC   13.06 (+2.19%)
GE   104.55 (+0.67%)
AMD   121.63 (-0.53%)
MU   69.69 (+2.12%)
T   25.50 (+1.76%)
F   17.00 (+9.61%)
ACB   6.98 (+2.05%)
DIS   170.20 (+0.38%)
PFE   43.29 (+0.74%)
BA   206.40 (-0.10%)
AMC   35.24 (+1.38%)
S&P 500   4,590.06 (+0.84%)
DOW   35,676.27 (+0.52%)
QQQ   383.15 (+0.83%)
AAPL   152.45 (+2.42%)
MSFT   322.85 (-0.10%)
FB   314.45 (+0.71%)
GOOGL   2,905.86 (-0.63%)
TSLA   1,069.50 (+3.05%)
AMZN   3,431.77 (+1.16%)
NVDA   246.62 (+0.86%)
BABA   169.75 (+0.31%)
NIO   39.82 (+1.30%)
CGC   13.06 (+2.19%)
GE   104.55 (+0.67%)
AMD   121.63 (-0.53%)
MU   69.69 (+2.12%)
T   25.50 (+1.76%)
F   17.00 (+9.61%)
ACB   6.98 (+2.05%)
DIS   170.20 (+0.38%)
PFE   43.29 (+0.74%)
BA   206.40 (-0.10%)
AMC   35.24 (+1.38%)
S&P 500   4,590.06 (+0.84%)
DOW   35,676.27 (+0.52%)
QQQ   383.15 (+0.83%)
AAPL   152.45 (+2.42%)
MSFT   322.85 (-0.10%)
FB   314.45 (+0.71%)
GOOGL   2,905.86 (-0.63%)
TSLA   1,069.50 (+3.05%)
AMZN   3,431.77 (+1.16%)
NVDA   246.62 (+0.86%)
BABA   169.75 (+0.31%)
NIO   39.82 (+1.30%)
CGC   13.06 (+2.19%)
GE   104.55 (+0.67%)
AMD   121.63 (-0.53%)
MU   69.69 (+2.12%)
T   25.50 (+1.76%)
F   17.00 (+9.61%)
ACB   6.98 (+2.05%)
DIS   170.20 (+0.38%)
PFE   43.29 (+0.74%)
BA   206.40 (-0.10%)
AMC   35.24 (+1.38%)
NASDAQ:ALZN

Alzamend Neuro Stock Forecast, Price & News

$2.07
+0.03 (+1.47 %)
(As of 10/28/2021 10:38 AM ET)
Add
Compare
Today's Range
$2.06
$2.10
50-Day Range
$2.26
$4.07
52-Week Range
$2.04
$33.55
Volume
1,282 shs
Average Volume
2.52 million shs
Market Capitalization
$179.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive ALZN News and Ratings via Email

Sign-up to receive the latest news and ratings for Alzamend Neuro and its competitors with MarketBeat's FREE daily newsletter.


About Alzamend Neuro

Alzamend Neuro, Inc., a preclinical stage biopharmaceutical company, focuses on developing products for the treatment of neurodegenerative diseases and psychiatric disorders. The company's lead product candidate is AL001 for the treatment of Alzheimer's and other neurodegenerative diseases and psychiatric disorders. It is also developing AL002, a cell-based therapeutic vaccine, which seeks to restore the ability of the patient's immunological system to Alzheimer's. The company was incorporated in 2016 and is headquartered in Tampa, Florida.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALZN
Employees
3
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$179.86 million
Next Earnings Date
N/A
Fiscal Year End
December 31
Optionable
Not Optionable

MarketRank

Overall MarketRank

2.03 out of 5 stars

Medical Sector

550th out of 1,372 stocks

Pharmaceutical Preparations Industry

258th out of 669 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












Alzamend Neuro (NASDAQ:ALZN) Frequently Asked Questions

Is Alzamend Neuro a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alzamend Neuro in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Alzamend Neuro stock.
View analyst ratings for Alzamend Neuro
or view top-rated stocks.

What stocks does MarketBeat like better than Alzamend Neuro?

Wall Street analysts have given Alzamend Neuro a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Alzamend Neuro wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Alzamend Neuro?

Alzamend Neuro saw a increase in short interest in the month of October. As of October 15th, there was short interest totaling 631,400 shares, an increase of 126.2% from the September 30th total of 279,100 shares. Based on an average daily trading volume, of 2,250,000 shares, the days-to-cover ratio is presently 0.3 days. Approximately 1.6% of the company's stock are sold short.
View Alzamend Neuro's Short Interest
.

What price target have analysts set for ALZN?

1 equities research analysts have issued 12-month price targets for Alzamend Neuro's stock. Their forecasts range from $8.00 to $8.00. On average, they anticipate Alzamend Neuro's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 292.2% from the stock's current price.
View analysts' price targets for Alzamend Neuro
or view top-rated stocks among Wall Street analysts.

Who are Alzamend Neuro's key executives?

Alzamend Neuro's management team includes the following people:
  • Mr. Stephan Jackman, CEO & Director (Age 45, Pay $200k)
  • Mr. Kenneth S. Cragun CPA, CFO & Treasurer (Age 60, Pay $86.67k)
  • Mr. Henry C.W. Nisser Esq., Exec. VP, Gen. Counsel & Director (Age 52, Pay $50k)
  • Mr. Milton Charles Ault III, Founder & Exec. Chairman (Age 51)
  • Ms. Lien T. Escalona, Chief Financial Officer
  • Mr. David J. Katzoff, Chief Operating Officer (Age 59)

When did Alzamend Neuro IPO?

(ALZN) raised $12 million in an IPO on Tuesday, June 15th 2021. The company issued 2,500,000 shares at $5.00 per share. Spartan Capital Securities, LLC acted as the underwriter for the IPO and -- was co-manager.

What is Alzamend Neuro's stock symbol?

Alzamend Neuro trades on the NASDAQ under the ticker symbol "ALZN."

When does Alzamend Neuro's lock-up period expire?

Alzamend Neuro's lock-up period expires on Monday, December 13th. Alzamend Neuro had issued 2,500,000 shares in its initial public offering on June 15th. The total size of the offering was $12,500,000 based on an initial share price of $5.00. After the expiration of Alzamend Neuro's lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

How do I buy shares of Alzamend Neuro?

Shares of ALZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alzamend Neuro's stock price today?

One share of ALZN stock can currently be purchased for approximately $2.04.

How much money does Alzamend Neuro make?

Alzamend Neuro has a market capitalization of $177.25 million.

How many employees does Alzamend Neuro have?

Alzamend Neuro employs 3 workers across the globe.

What is Alzamend Neuro's official website?

The official website for Alzamend Neuro is www.alzamend.com.

How can I contact Alzamend Neuro?

The company can be reached via phone at 844-722-6303.


This page was last updated on 10/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.